Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neuronetics ( (STIM) ) has issued an update.
On April 1, 2026, Neuronetics entered into an Executive Consulting and Release Agreement with retiring president and chief executive Keith J. Sullivan, under which he will provide consulting services through March 31, 2027 without additional pay while continuing to vest in existing equity awards, and will remain bound by non-compete, non-solicit and confidentiality covenants. On April 2, 2026, the company began a workforce reduction affecting up to 5% of employees, expecting roughly $0.2 million in second-quarter restructuring charges and annualized savings of $2.5 million to $3.0 million as part of a broader cost-optimization drive.
On March 31, 2026, chief financial officer and treasurer Steven E. Pfanstiel notified Neuronetics he would resign effective May 1, 2026 to pursue an external opportunity, with the company launching a search for his successor and stressing that his departure was not due to any disagreement over operations or policies. On April 6, 2026, Neuronetics publicly announced the CFO transition and, despite simultaneous executive turnover and headcount cuts, reaffirmed the financial guidance it had provided on March 17, 2026, signaling management’s confidence in its current outlook and cost-reduction program for fiscal 2026.
The most recent analyst rating on (STIM) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Neuronetics stock, see the STIM Stock Forecast page.
Spark’s Take on STIM Stock
According to Spark, TipRanks’ AI Analyst, STIM is a Neutral.
The score is primarily constrained by weak financial fundamentals—ongoing losses and persistent cash burn despite improving revenue and reduced debt. Technicals also remain bearish with the stock trading below key moving averages and negative MACD. The earnings call improves the outlook with growth guidance and a stated path to positive operating cash flow in H2 2026, but margin pressure and legal/reimbursement risks keep the overall score below average.
To see Spark’s full report on STIM stock, click here.
More about Neuronetics
Neuronetics, Inc., based in Malvern, Pa., is a medical technology company focused on designing, developing and marketing treatments for neurohealth disorders. Its flagship non-drug, noninvasive NeuroStar Advanced Therapy System is a leading transcranial magnetic stimulation solution for major depressive disorder, supported by extensive clinical data and outcomes registries.
In addition to selling NeuroStar systems and treatment sessions, Neuronetics operates Greenbrook TMS treatment centers across the United States, where it offers NeuroStar therapy for major depressive disorder and other mental health conditions. These centers also provide SPRAVATO (esketamine) nasal spray for treatment-resistant depression and depressive symptoms associated with major depressive disorder in adults.
Average Trading Volume: 2,117,473
Technical Sentiment Signal: Sell
Current Market Cap: $105.3M
For an in-depth examination of STIM stock, go to TipRanks’ Overview page.